$0.17 EPS Expected for AngioDynamics, Inc. (ANGO)

December 26, 2017 - By Richard Conner

 $0.17 EPS Expected for AngioDynamics, Inc. (ANGO)
Investors sentiment decreased to 1.17 in Q3 2017. Its down 1.32, from 2.49 in 2017Q2. It is negative, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Rothschild Asset Mngmt Inc reported 118,312 shares. Nordea Investment Management Ab holds 126,040 shares. 65,859 were accumulated by Morgan Stanley. Brinker Inc owns 14,939 shares. California Pub Employees Retirement Sys reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Ls Inv Ltd Limited Liability Company stated it has 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Teachers Retirement Sys Of The State Of Kentucky reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). New York-based Spark Invest Mngmt Ltd Liability Com has invested 0.11% in AngioDynamics, Inc. (NASDAQ:ANGO). Gamco Inc Et Al holds 50,000 shares. Tudor Inv Corp Et Al has invested 0.02% in AngioDynamics, Inc. (NASDAQ:ANGO). Invesco Limited owns 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 150,853 shares. Voya Lc invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Fenimore Asset Mgmt Inc owns 590,775 shares or 0.41% of their US portfolio. Ny State Common Retirement Fund accumulated 43,720 shares or 0% of the stock. Bessemer Gru Inc Inc holds 0% or 63,200 shares in its portfolio.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on January, 4 before the open.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $6.24M giving it 24.46 P/E if the $0.17 EPS is correct. After having $0.12 EPS previously, AngioDynamics, Inc.’s analysts see 41.67 % EPS growth. The stock decreased 0.60% or $0.1 during the last trading session, reaching $16.63. About 112,615 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since December 26, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. AngioDynamics had 18 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Monday, August 31 by Zacks. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Wednesday, May 31. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Mkt Perform” rating given on Tuesday, November 10 by Raymond James. KeyBanc Capital Markets maintained the shares of ANGO in report on Thursday, August 24 with “Hold” rating. On Monday, July 10 the stock rating was maintained by Canaccord Genuity with “Hold”. On Tuesday, July 18 the stock rating was maintained by Canaccord Genuity with “Hold”. The firm has “Neutral” rating given on Wednesday, September 23 by Sidoti. As per Thursday, September 28, the company rating was maintained by KeyBanc Capital Markets. As per Tuesday, April 5, the company rating was downgraded by Canaccord Genuity. The firm earned “Equal-Weight” rating on Wednesday, July 19 by Barclays Capital.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $610.58 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 167.98 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Businesswire.com, which released: “AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on …” on December 11, 2017. Businesswire.com‘s article titled: “AngioDynamics to Present at the JP Morgan Healthcare Conference” and published on December 11, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: